Boryung Pharm Total Liabilities
Boryung Pharm total liabilities. Based on the latest financial reports, Boryung Pharm (003850) has total liabilities worth ₩537.67 Billion KRW (≈ $364.37 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Boryung Pharm liquidity resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Boryung Pharm (2009–2024)
Total liabilities of Boryung Pharm from 2009 to 2024. This chart illustrates how Boryung Pharm's total liabilities have evolved over time, based on quarterly financial data. Explore 003850 strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
Boryung Pharm Competitors by Total Liabilities
The table below lists competitors of Boryung Pharm ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
SWS Hemodialysis Care Co. Ltd. A
SHG:688410
|
China | CN¥349.56 Million |
|
One Liberty Properties Inc
NYSE:OLP
|
USA | $557.77 Million |
|
Studio Dragon Corporation
KQ:253450
|
Korea | ₩234.22 Billion |
|
Hume Industries Berhad
KLSE:5000
|
Malaysia | RM329.57 Million |
|
Zhejiang Jindao Technology Co. Ltd.
SHE:301279
|
China | CN¥421.01 Million |
|
Gravity Co Ltd
NASDAQ:GRVY
|
USA | $105.30 Billion |
|
Shanxi Antai Group Co Ltd
SHG:600408
|
China | CN¥3.07 Billion |
|
Cantor Equity Partners IV, Inc. Class A Ordinary Shares
NASDAQ:CEPF
|
USA | $265.50K |
Liability Composition Analysis (2009–2024)
This chart breaks down Boryung Pharm's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Boryung Pharm total assets.
Liquidity & Leverage Metrics
Boryung Pharm Total Liabilities Ratios Explained
Boryung Pharm total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.39 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.66 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.40 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Boryung Pharm's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Boryung Pharm (2009–2024)
The table below shows the annual total liabilities of Boryung Pharm from 2009 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩379.58 Billion ≈ $257.24 Million |
+3.64% |
| 2023-12-31 | ₩366.26 Billion ≈ $248.21 Million |
-2.58% |
| 2022-12-31 | ₩375.97 Billion ≈ $254.79 Million |
+6.11% |
| 2021-12-31 | ₩354.33 Billion ≈ $240.12 Million |
+15.15% |
| 2020-12-31 | ₩307.71 Billion ≈ $208.53 Million |
+36.96% |
| 2019-12-31 | ₩224.68 Billion ≈ $152.26 Million |
+15.86% |
| 2018-12-31 | ₩193.91 Billion ≈ $131.41 Million |
+26.86% |
| 2017-12-31 | ₩152.86 Billion ≈ $103.59 Million |
-24.53% |
| 2016-12-31 | ₩202.55 Billion ≈ $137.27 Million |
+59.22% |
| 2012-12-31 | ₩127.21 Billion ≈ $86.21 Million |
+2.25% |
| 2011-12-31 | ₩124.42 Billion ≈ $84.32 Million |
+13.68% |
| 2010-12-31 | ₩109.45 Billion ≈ $74.17 Million |
+107.40% |
| 2009-12-31 | ₩52.77 Billion ≈ $35.76 Million |
-- |
About Boryung Pharm
Boryung Corporation engages in the manufacture and sale of pharmaceutical products in South Korea and internationally. It offers prescription drugs for hypertension, dyslipidemia, and diabetes drugs. The company was formerly known as Boryung Pharmaceutical Co., Ltd. and changed its name to Boryung Corporation in March 2022. Boryung Corporation was founded in 1957 and is headquartered in Seoul, So… Read more